Fosamax Femur Fractures

In addition to osteonecrosis of the jaw (“ONJ”) and musculoskeletal pain, Fosamax, a popular bisphosphonate used to treat osteoporosis and osteopenia, is also linked to femur fractures.  A wave of recent studies have concluded that long-term use of the bisphosphonate can cause a Fosamax femur fracture.  Fosamax fractures can occur during low impact activities.  Fosamax femur fractures are particularly unusual since the femur is one of the strongest bones in the body and thus one of the hardest to break.

If you or a loved one sustained a Fosamax femur fracture, you may be able to file a lawsuit seeking compensation for your medical expenses, pain and suffering, lost wages and more.  The lawyers at Bernstein Liebhard are currently investigating and filing lawsuits on behalf of individuals who sustained a Fosamax hip fracture.  Contact one of our Fosamax femur fracture attorneys for a free and confidential case review.

Fosamax fractures are most likely to occur in women who take Fosamax for an extended period of time.  Dr. Joseph Lane, chief of metabolic bone disease at the Hospital for Special Surgery, explained the link between a femur fracture and Fosamax use, “Normally your bone is constantly being remade . . . These patients don’t remake their bone and they acquire damage, microdamage, the collagen gets altered and we need to rejuvenate the skeleton.”  According to research by Dr. Rossenwasser, an orthopedic surgeon at New York-Presbyterian Hospital Columbia Campus, problems from bisphosphonate use begin to appear a few years after patients start taking the medication.  In the research he presented on the link between femur fracture and Fosamax use at the 2010 Conference of the American Academy of Orthopedic Surgeons, he stated, “In the early treatment period, patients using bisphosphonates experienced improvements in all parameters, including decreased buckling ratio and increased cross-sectional area … However, after four years of use, these trends reversed, revealing an association between prolonged therapy and declining cortical bone structural integrity.”

FDA’s Reaction To Fosamax Femur Fractures

In 2008, the U.S. Food and Drug Administration (“FDA”) reached out to Merck, the manufacturer of Fosamax, about the link between a patient experiencing a femur fracture and Fosamax use.  Sixteen months later, the company issued a warning in its drug package insert to include a Fosamax hip fracture as one of the drug’s “adverse events.”  Some medical experts believe that Merck took too long to respond to Fosamax femur fracture and Fosamax hip fracture concerns.

Femur fracture Fosamax risks have since been the subject of increased media attention and heightened scrutiny by the FDA.  On March 3, 2010, the FDA issued a Drug Safety Communication regarding Fosamax fractures.  It stated, “At this point, the data that FDA has reviewed has not shown a clear connection between bisphosphonate use and a risk of atypical subtrochanteric femur fractures.  FDA is working closely with outside experts, including members of the recently convened American Society of Bone and Mineral Research Subtrochanteric Femoral Fracture Task Force, to gather additional information that may provide more insight into this issue.”  After further review, in October 2010, the FDA issued a Fosamax femur fracture warning that Fosamax and other bisphosphonates put patients at risk for atypical thigh bone (femur) fractures.

Fosamax Femur Fracture Lawyers

If you or a loved one has suffered a femur fracture after or while taking Fosamax you may be entitled to financial compensation due to Fosamax femur damage.  Please contact us for a free evaluation of your rights and options regarding Fosamax femur fractures.

Published November 17, 2011 by